Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

Research and Innovation Action · Running

ARTILLERY Artificial Intelligence for early detection of non-communicable disease risk in people with breast cancer

Coordinator
Universitair Medisch Centrum Utrecht, Netherlands
Runs
1 May 2023 to 30 April 2028
Status
Running
EU funding
€5.7m
Total cost
€5.7m
Partners
11 organisations in 5 countries
Type
Research and Innovation Action
Grant agreement
101080983

What the project is doing

In the project's own words, from its summary on CORDIS.

The ultimate ambition of the ARTILLERY consortium is to enhance long term health of the growing population of breast cancer survivors by making optimal use of routine imaging for timely detection of actionable chronic conditions or their risk factors. ARTILLERY will develop trustworthy AI systems that allow robust and accurate risk prediction of common chronic conditions, including cardiovascular disease, chronic obstructive pulmonary disease, unfavorable body composition and osteoporosis.

Implementation of these AI systems in routine care will provide healthcare professionals with objective and quantitative parameters of their patients’ individual chronic disease risks, permitting them to start prompt treatment and implement risk reducing strategies. Unique aspects of ARTILLERY include the continuous and close interaction between renowned computational scientists, influential breast cancer professionals and the largest breast cancer patient advocacy organisation in Europe, as well as direct access to a large and comprehensive Real-World Data infrastructure that includes CT scans and clinical data from >26.000 patients with breast cancer.

This partnership will result in trustworthy AI systems for prevalent chronic conditions, relevant to breast cancer patients and physicians, and ready for implementation at radiotherapy workstations across Europe. ARTILLERY-manuals will be developed and made available to multidisciplinary tumour boards and will contain recommendations on how and when (not) to use AI systems in routine breast cancer care, and on optimal management of breast cancer patients identified to be at high risk of chronic conditions.

At the end of the project, we will have augmented the understanding and perception of the public towards the use of AI systems in routine healthcare and empowered breast cancer patients to make targeted lifestyle changes based on their individual risk profile, thus improving their life expectancy and quality of life.

Topics

Who is involved

OrganisationCityCountryRole
Universitair Medisch Centrum UtrechtUtrechtNetherlandsCoordinator
Klinikum Der Ludwig-Maximilians-Universitat MunchenMunchenGermanyThird party
Ludwig-Maximilians-Universitaet MuenchenPlaneggGermanyParticipant
Kobenhavns UniversitetKobenhavnDenmarkParticipant
Region HovedstadenHillerodDenmarkParticipant
Quantib BVRotterdamNetherlandsParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsParticipant
Fundacao D. Anna De Sommer Champalimaud E Dr. Carlos Montez ChampalimaudLisboaPortugalParticipant
Europa Donna Slovensko Zdruzenje Za Boj Proti Raku DojkLjubljanaSloveniaParticipant
Inteliteh Inteligentne Tehnologije D.o.o.LjubljanaSloveniaParticipant
Univerza V LjubljaniLjubljanaSloveniaParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI